

VolitionRx

11:21 27 May 2020

VolitionRx CEO to present coronavirus white blood cell research at Maxim Group virtual conference

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Wednesday that CEO Cameron Reynolds has been invited to give a presentation on coronavirus testing Wednesday at The Role of Cell Therapy and Clarity on Testing Conference.

The virtual event, put on by the Maxim Group, runs from 10 am to 2 pm ET. Reynolds is part of a panel discussion titled "Testing & Susceptibility - Clearing the Air," set to begin at noon.

Reynolds plans to talk about Volition's research on white blood cells and their predictive potential regarding the coronavirus.

READ: VolitionRx closes \$13.8M public offering to fund product development and clinical studies

Under normal circumstances, neutrophil extracellular traps (NETs) are formed by white blood cells to catch and trap invading viruses by ejecting chromatin materials. Viruses like SARS and pneumonia, though, are associated with a hyperimmune response that sees white blood cells eject massive amounts of NETs, which is damaging to the lungs.

VolitionRx is currently clinically testing whether elevated levels of neuroendocrine tumors (NETs) in the blood are predictive of complications arising from viral infections such as COVID-19.

So far, a proof of concept study of 34 coronavirus patients and 50 control group subjects revealed that nucleosomes, a basic structural unit of DNA, were highly elevated in those with the virus.

A preliminary study showed an area under the curve (AUC) — a measure of drug exposure — for one of its NU.Q assays of 98.7% for PCR positive COVID versus the control group with 100% sensitivity and 94% specificity. A second assay showed an AUC of 86.2%.

The company plans to use the results of this trial and other ongoing studies to further its efforts to develop a clinically useful product to help mitigate the pandemic, the company said.


Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 3.24

Market Cap: \$155.26 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	6.17	2.22

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. .

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).